Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Arrowhead Pharmaceuticals, Inc., Krystal Biotech or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Latest Biotechnology and Arrowhead Pharmaceuticals, Inc., Krystal Biotech, Inc. Stock News

As of July 31, 2026, Arrowhead Pharmaceuticals, Inc. had a $11.9 billion market capitalization, compared to the Biotechnology median of $252.6 million. Arrowhead Pharmaceuticals, Inc.’s stock is up 27.5% in 2026, down 1.1% in the previous five trading days and up 439% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc. does not have a price-earnings ratio. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $622.0 million with a -48.4% net profit margin. Year-over-year quarterly sales growth most recently was -86.4%. Analysts expect adjusted earnings to reach $-3.110 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 31, 2026, Krystal Biotech, Inc. had a $10.1 billion market cap, putting it in the 77th percentile of all stocks. Krystal Biotech, Inc.’s stock is up 38.4% in 2026, up 1.8% in the previous five trading days and up 122.63% in the past year.

Currently, Krystal Biotech, Inc.’s price-earnings ratio is 45.7. Krystal Biotech, Inc.’s trailing 12-month revenue is $417.3 million with a 53.9% net profit margin. Year-over-year quarterly sales growth most recently was 32.0%. Analysts expect adjusted earnings to reach $8.206 per share for the current fiscal year. Krystal Biotech, Inc. does not currently pay a dividend.

How We Compare Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc. Growth Grades

Company	Ticker	Growth
Arrowhead Pharmaceuticals, Inc.	ARWR	F
Krystal Biotech, Inc.	KRYS	na

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Arrowhead Pharmaceuticals, Inc. has a Growth Score of 13, which is Very Weak. Krystal Biotech, Inc. does not have a meaningful Growth Score.

The Growth Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Krystal Biotech or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Krystal Biotech or Inc. is the better investment when it comes to sustainable growth.

Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc.’s Momentum Grades

Company	Ticker	Momentum
Arrowhead Pharmaceuticals, Inc.	ARWR	A
Krystal Biotech, Inc.	KRYS	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Arrowhead Pharmaceuticals, Inc. has a Momentum Score of 98, which is Very Strong. Krystal Biotech, Inc. has a Momentum Score of 92, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Arrowhead Pharmaceuticals, Inc.	ARWR	D
Krystal Biotech, Inc.	KRYS	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Arrowhead Pharmaceuticals, Inc. has a Earnings Estimate Score of 40, which is Negative. Krystal Biotech, Inc. has a Earnings Estimate Score of 52, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Krystal Biotech or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Krystal Biotech or Inc. is the better investment when it comes to estimate revisions.

Other Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc. Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Arrowhead Pharmaceuticals, Inc., Krystal Biotech or Inc. Stock?

Overall, Arrowhead Pharmaceuticals, Inc. stock has a Growth Score of 13, Momentum Score of 98 and Estimate Revisions Score of 40.

Krystal Biotech, Inc. stock has a Growth Score of , Momentum Score of 92 and Estimate Revisions Score of 52.

Comparing Arrowhead Pharmaceuticals, Inc., Krystal Biotech and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.